Search / Trial NCT06611020

Adjuvant VaccInation After Conization for the Treatment for CervicAL Dysplasia

Launched by FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI, MILANO · Sep 20, 2024

Trial Information

Current as of October 08, 2024

Recruiting

Keywords

Hpv

Description

Patients treated for HPV-related disease are counseled about the potential protective role of HPV vaccination. The investigators will monitor the risk of HPV recurrence in pateints who choce to have vaccination and who did not.

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • * Treatment of HPV-related disease
  • Exclusion Criteria:
  • * Previous HPV vaccination

About Fondazione Irccs Istituto Nazionale Dei Tumori, Milano

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano is a leading cancer research and treatment institution in Italy, dedicated to advancing the understanding and management of oncological diseases. As a prominent clinical trial sponsor, the foundation focuses on innovative research aimed at developing new therapeutic strategies and improving patient outcomes. With a commitment to translational medicine, it collaborates with a network of national and international partners to facilitate cutting-edge clinical trials, enhance cancer care, and contribute to the global body of oncological knowledge.

Locations

Milano, Lombardia, Italy

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0